Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03474549 · ClinicalTrials.gov registry record · NA
Treatment With Intent to Generate Endovascular Reperfusion
A NA study of Ischemic Stroke, sponsored by Rapid Medical.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 17
- Study locations
NCT03474549: Completed NA study of Ischemic Stroke, sponsored by Rapid Medical.
NCT03474549 is a NA study of Ischemic Stroke that has completed, run by Rapid Medical. The registered enrollment target is 160 participants, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (89% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03474549, a NA study of Ischemic Stroke, has completed, sponsored by Rapid Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 17
- Study locations
Study Summary
Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment. The objective of the TIGER Study is to evaluate the safety and effectiveness of the Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke due to a large vessel occlusion (LVO). This study is designed to support substantial equivalence to approved and marketed products such as the Solitaire or Trevo Retriever.
Primary Outcome
Effectiveness (Successful reperfusion)
Conditions Studied
Interventions
- DEVICE Tigertriever revascularization device
Study Locations (17)
Florida
- Tenet Health - Coral Springs
- Baptist Health Research Institute - Jacksonville
- Baptist Health South Florida - Miami
- University of Miami - Miami
California
- UCLA medical center - Los Angeles
- Los Robles - Thousand Oaks
New York
- Maimonides Medical Center - Brooklyn
- University of Buffalo - Buffalo
Ohio
- Riverside Methodist Hospital - Columbus
- Mercy Health - Toledo
Georgia
- WellStar Research Institute - Marietta
Iowa
- University of Iowa - Iowa City
Massachusetts
- University of Massachusetts - Worcester
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
What the finished NCT03474549 record still lists
NCT03474549 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Tigertriever revascularization device is the first listed.
NCT03474549 lists 17 locations in 11 states (Florida, California, New York).
Frequently Asked Questions
What is clinical trial NCT03474549 about?
NCT03474549 is a clinical study titled "Treatment With Intent to Generate Endovascular Reperfusion". Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are cand...
What is the current status of trial NCT03474549?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2018-05-09. Estimated completion is 2020-06-30.
What conditions does trial NCT03474549 study?
This clinical trial studies the following conditions: Ischemic Stroke.
What interventions are being tested in trial NCT03474549?
The interventions under investigation include: Tigertriever revascularization device (DEVICE).
Who is sponsoring clinical trial NCT03474549?
This trial is sponsored by Rapid Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03474549 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03474549's enrollment target sits among peer trials
160 25th of 66 higher than 42 of 66 other Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Of Vagus Nerve Stimulation (VNS) With Mobility Training For Gait Recovery After Chronic Ischemic Stroke
RECRUITING · NA
-
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
RECRUITING · NA
-
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
StrokeNet Thrombectomy Endovascular Platform
RECRUITING · NA
-
Virtual Reality Based Rehabilitation After Ischemic Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI